Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Published byEdwin Lewis Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy."— Presentation transcript:

1 Figure 1. Dose modification scheme for the second cycle of capecitabine treatment.
From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4): doi: /annonc/mdr329 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

2 Figure 2. Dose modification diagram in all enrolled patients (N = 82).
From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4): doi: /annonc/mdr329 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

3 Figure 3. The change in dose intensity during capecitabine chemotherapy (mean and standard error, mg/m<sup>2</sup>/day). From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4): doi: /annonc/mdr329 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

4 Figure 4. Kaplan–Meier curves of disease-free survival (A), recurrence-free survival (B), and overall survival (C). From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4): doi: /annonc/mdr329 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

5 Figure 5. The mean scores (circle) and standard deviation (bar) of scales and items of the QLQ-C30 just before the adjuvant chemotherapy (N = 57). One global scale (QL) and five functional scales, including physical functioning (PF), role functioning (RF), emotional functioning (EF), cognitive functioning (CF), and social functioning (SF), are shown on the left side; a higher score reflects a better level of functioning. Nine symptom scales, including fatigue (FA), nausea and vomiting (NV), pain (PA), dyspnea (DY), sleep disturbance (SL), appetite loss (AP), constipation (CO), diarrhea (DI), and financial difficulties (FI), are shown on the right side; a higher score represents a worse level of symptom. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4): doi: /annonc/mdr329 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

6 Figure 6. (A) The changes of quality of life (QoL) scores in five functional and one global scales and (B) the changes of QoL scores in nine symptom scales. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4): doi: /annonc/mdr329 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

Download ppt "Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy."

Similar presentations

How to manage suspected cancer

How to manage suspected cancer
Fig. 1. Flow diagram of study participants and outcomes.

Fig. 1. Flow diagram of study participants and outcomes.
From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.
Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.

Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.
Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)

Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)
Error bars represent the mean (s.e.).

Error bars represent the mean (s.e.).
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Figure 3. Examples of tweets classified as ridicule.

Figure 3. Examples of tweets classified as ridicule.
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Similar presentations

Ads by Google